Antinociceptive effects of central administration of the endogenous cannabinoid receptor type 1 agonist VDPVNFKLLSH-OH [(m)VD-hemopressin(α)], an N-terminally extended hemopressin peptide

MLA

Zilong Wang, et al. “Antinociceptive Effects of Central Administration of the Endogenous Cannabinoid Receptor Type 1 Agonist VDPVNFKLLSH-OH [(m)VD-Hemopressin(α)], an N-Terminally Extended Hemopressin Peptide.” The Journal of Pharmacology and Experimental Therapeutics, vol. 348, no. 2, Dec. 2013. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....2f0a0ae057f2a5838e02864ffa301f29&authtype=sso&custid=ns315887.

APA

Zilong Wang, Hong-zhu Tang, Ning Li, Rui Wang, Xu-Hui Li, Jia-xin Pan, Quan Fang, Xue-mei Chang, & Zheng-lan Han. (2013). Antinociceptive effects of central administration of the endogenous cannabinoid receptor type 1 agonist VDPVNFKLLSH-OH [(m)VD-hemopressin(α)], an N-terminally extended hemopressin peptide. The Journal of Pharmacology and Experimental Therapeutics, 348(2).

Chicago

Zilong Wang, Hong-zhu Tang, Ning Li, Rui Wang, Xu-Hui Li, Jia-xin Pan, Quan Fang, Xue-mei Chang, and Zheng-lan Han. 2013. “Antinociceptive Effects of Central Administration of the Endogenous Cannabinoid Receptor Type 1 Agonist VDPVNFKLLSH-OH [(m)VD-Hemopressin(α)], an N-Terminally Extended Hemopressin Peptide.” The Journal of Pharmacology and Experimental Therapeutics 348 (2). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....2f0a0ae057f2a5838e02864ffa301f29&authtype=sso&custid=ns315887.